Provexis has continued working with the University of Oslo undertaking further research into the relationship between Fruitflow – aheart-health functional food ingredient – and blood pressure regulation.
The company and the University have now conducted a small clinical trial in Oslo to examine the acute effects of different amounts of Fruitflow in powder format on parameters relating to blood pressure. The trial patients – who were healthy with no underlying cardiovascular disease or other conditions likely to affect blood pressure – received both placebo and Fruitflow supplements in a blinded crossover design.
Results from the study showed that a 150mg dose of Fruitflow in powder format significantly lowered the average 24-hour systolic blood pressure compared to placebo. Pressure was also significantly lower during the sleeping period.
Raised blood pressure is estimated to cause more than 7 million premature deaths throughout the world each year, and 4.5% of the disease burden. These pilot study results show that Fruitflow may have clinically relevant effects in blood pressure control.
The Company expects that these encouraging pilot study results will be of relevance to a large number of consumers and patients, with further commercial interest expected from existing and potential future brand owner trade customers.
Dawson Buck, Chairman of Provexis, said: “We are delighted to announce the results from the second stage of our collaboration work with the University of Oslo, a pilot study which indicated that a standard dose of Fruitflow® in powder format significantly lowered average 24-hour systolic blood pressure compared to placebo. Both systolic and diastolic blood pressure were shown to be significantly lower whilst trial subjects were awake, a clinically relevant reduction in blood pressure which is expected to be of interest to a large number of consumers and patients with a wide range of cardiovascular conditions.
The results further demonstrate that Fruitflow has the potential to play an import role across all major global markets in the primary prevention of cardiovascular disease.
The company said it expected these encouraging blood pressure results to have a positive effect on current and future commercial negotiations for Fruitflow, and it will seek to maximise the commercial opportunities arising from this important development for Fruitflow and the Provexis business,” said Buck
Below, you can watch a video about Frutiflow.
